Recent Updates
Recently added Catalysts
CRVS Positive Sentiment Score: 60/100

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Tuesday, October 28, 2025 1 min read
Key Takeaway: Corvus Pharmaceuticals has announced a conference call scheduled for November 4, 2025, to provide a business update and report its financial results for the third quarter of 2025. The event will be accessible to the public through a toll-free phone line and a webcast. Corvus is noted for its clinical-stage development of ITK inhibitors as an innovative strategy in immunotherapy targeting cancer and immune diseases. The company aims to enhance investor engagement by providing timely updates on its progress.

Market Sentiment Analysis

POSITIVE FACTORS

  • Corvus Pharmaceuticals is set to provide an update, indicating ongoing developments.
  • The conference call allows investors to directly engage and access new information.
  • The company's focus on ITK inhibition represents a novel approach in cancer treatment.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on November 4, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report third quarter 2025 financial results.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website.  A replay of the webcast will be available on Corvus’ website for 90 days.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
llea@corvuspharma.com
sseapy@realchemistry.com

Frequently Asked Questions

When is Corvus Pharmaceuticals' conference call scheduled?

The conference call is on November 4, 2025, at 4:30 pm ET.

How can I access the conference call?

You can dial 1-800-717-1738 for domestic or 1-646-307-1865 for international access.

Where can I find the live webcast of the event?

The live webcast is available in the investor relations section of Corvus' website.

What is the lead product candidate of Corvus Pharmaceuticals?

Corvus' lead product candidate is soquelitinib, an investigational oral drug.

Is there a replay available for the webcast?

Yes, the webcast replay will be accessible on Corvus' website for 90 days.

Tags: CRVS Viatris Investor Conferences Healthcare Corvus Pharmaceuticals third quarter results financial update immunotherapy
Last updated: Oct 28, 2025